ClinicalTrials.gg
RecruitingNCT07056777Updated Jun 30, 2026

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer

A Phase 1/2 interventional study of DR30206 and Oxaliplatin in Gastrointestinal Cancer, sponsored by Zhejiang Doer Biologics Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Zhejiang Doer Biologics Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2025, registered Jun 2025).
  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
186
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 110 studies in Gastrointestinal Neoplasms with a site in China — 44 open to participants now, 51 under way, 6 of them phase 3. Gastrointestinal Neoplasms · China.

Planned enrollment
33rd of 88
186 · median 120
Started
2025
with 7 others
Phase 1/2
10 of 110
6 open now
Primary completion
2027-04
later than 28 of 50 live
Registered
94th of 110
by date

Among the 110 studies in Gastrointestinal Neoplasms with a site in China, this one is the 33rd largest by planned enrollment of the 88 interventional ones that give a count, is one of 8 that started in 2025, is one of 10 in phase 1/2, reaches primary completion later than 28 of the 50 other live ones, and was the 94th registered.

Gastrointestinal Neoplasms

697 studies on the registry are indexed under Gastrointestinal Neoplasms; 210 are open to participants now.

Browse Gastrointestinal Neoplasms studies →

Open to participants now

44 of the 110 studies in Gastrointestinal Neoplasms with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Gastrointestinal Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, open-label phase Ib/IIa clinical study conducted in China, aimed at evaluating the safety tolerance, efficacy, pharmacokinetic (PK) characteristics, and immunogenicity of DR30206 in combination with standard treatment regimens for advanced or metastatic gastrointestinal tumors.

Read the detailed description

This is a multicenter, open-label phase Ib/IIa clinical study conducted in China, aimed at evaluating the safety tolerance, efficacy, pharmacokinetic (PK) characteristics, and immunogenicity of DR30206 in combination with standard treatment regimens for advanced or metastatic gastrointestinal tumors.

The study consists of two phases: the dose escalation phase (phase Ib) and the dose expansion phase (phase IIa). Based on the tumor type and treatment approach of the participants, different cohorts are established within both the phases Ib and IIa.

03

Conditions studied

  • Gastrointestinal Cancer

Keywords

  • Gastrointestinal Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign a written form.
  2. Patients must be ≥ 18 and ≤75 years of age.
  3. (ECOG) performance status of 0 or 1.
  4. Expected survival period of at least 3 months.
  5. Depending on the tumor type, subjects must meet the following respective requirements:

    1. Colorectal cancer: i. or cytologically confirmed unresectable locally advanced or colorectal cancer; ii. Subjects who have not previously received systemic chemotherapy(except for left-sided colorectal cancer with wild-type RAS/BRAF); or subjects who have progressed after chemotherapy with or without targeted or immunotherapy.
    2. Other gastrointestinal tumors: i. Histologically or cytologically confirmed unresectable locally advanced or metastatic esophageal adenocarcinoma, gastric adenocarcinoma, or gastroesophageal junction adenocarcinoma, with -negative or low expression; ii. Subjects who have not previously received systemic chemotherapy; for patients who previously received chemotherapy, neoadjuvant chemotherapy, or radical chemoradiotherapy for advanced disease with curative intent, if disease progression occurs more than 6 months after the completion of the last treatment, they are eligible for this study.
  6. According to v1.1, subjects must have at least one .
  7. Adequate bone marrow, liver, and renal function.
  8. Male or female subjects with fertility must agree to take effective measures during the study period and within 180 days after the end of the last medication.
  9. Able to understand and follow the scheduled visits, treatments, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with MSI-H or dMMR.
  2. A history of severe allergic reactions to other monoclonal antibodies (mAb) or bispecific antibodies, or known allergies to any drug or its components in this study.
  3. Use of high-dose (>10 mg/day prednisone or equivalent doses of other corticosteroids) or other drugs within 14 days prior to the first administration of the investigational drug.
  4. Received the following treatments or medications within 28 days before starting the study treatment: a. Inoculate , or expect to receive such vaccines during the study treatment period or within 5 months after the last administration of the study treatment; b.Systemic treatment with anti-tumor drugs, or local anti-tumor therapy.
  5. Received local radiotherapy within 2 months prior to the first administration of investigational drug (palliative radiotherapy for bone completed more than 2 weeks before baseline tumor assessment is acceptable);
  6. Received non-specific immunomodulatory therapy (e.g., interleukins, interferons, thymosin, tumor necrosis factor, etc.) within 2 weeks prior to the first administration of investigational drug;
  7. Receipt of other investigational drugs or investigational medical devices within 28 days prior to the first administration of the investigational drug.
  8. Major surgery (defined as requiring general anesthesia and hospitalization for more than 24 hours) or severe traumatic injury within 28 days prior to the first administration of the investigational drug, or expected to require major surgery during the study period, except for minor procedures (e.g., tooth extraction, ) deemed not to affect participation in the study by the investigator.
  9. Presence of severe chronic or active infections within 28 days prior to the first administration of the investigational drug, including but not limited to hospitalization for infection, sepsis, or severe pneumonia complications, or any active infection that the investigator considers may affect the participant's safety; or systemic antibiotic therapy within 2 weeks prior to the start of treatment (routine prophylactic anti-infective therapy is exempt).
  10. Persistent toxicities ( 5.0 Grade 2 or higher, e.g., hyperpigmentation, alopecia, etc.), except for adverse reactions deemed to have no safety risk by the investigator, related to prior treatments (including systemic therapy, radiotherapy, or surgery).
  11. Presence of central nervous system (CNS) metastases and/or cancerous meningitis. Subjects who have received local treatment for may be considered for participation in this study provided that imaging confirms no disease progression within 4 weeks prior to the first administration of the investigational drug, all neurological symptoms are stable, there is no evidence of new or enlarging CNS metastases, and radiotherapy, surgery, or corticosteroid therapy for CNS metastases has been discontinued for at least 28 days prior to the first administration of the investigational drug. However, cancerous meningitis, regardless of clinical stability, should be excluded.
  12. virus infection (must meet both HBsAg positive and HBV-DNA > 500 IU/mL), virus infection (must meet both HCV-Ab positive and HCV-RNA positive), infection (HIV-Ab positive), active syphilis infection, active tuberculosis infection.
  13. There have been clinically significant cardiovascular and cerebrovascular diseases within 6 months prior to the first study drug dosing.
  14. Within 2 years prior to the first administration of the investigational drug, the subject has active diseases requiring systemic treatment (e.g., use of glucocorticoids or immunosuppressive drugs). Replacement therapies (e.g., levothyroxine, insulin, or physiological corticosteroid replacement for adrenal or pituitary insufficiency) are permitted.
  15. Within 3 years prior to the first administration of the investigational drug, the subject has a history of other , except those cured by definitive treatment with expectation of cure, such as basal or squamous cell skin cancer, localized low-risk prostate cancer, papillary thyroid cancer, or any in situ cancer treated by definitive resection (e.g., cervical intraepithelial neoplasia, ductal carcinoma in situ).
  16. The subjects have other severe or uncontrolled medical conditions, or the investigator deems the subject unsuitable for participation in this clinical trial or believes it would affect the subject's adherence to the study protocol, including but not limited to: a) History of or current concomitant severe respiratory diseases; b) Severe arterial or venous thromboembolic events within 6 months prior to the first investigational drug administration; c) Massive pleural effusion, ascites, or pericardial effusion with clinical symptoms or requiring symptomatic treatment within 28 days prior to the first investigational drug administration; d) Active or history of inflammatory bowel disease; e) History of severe peptic ulcer, gastrointestinal perforation, fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding, or esophageal or gastric variceal bleeding due to portal hypertension within 6 months prior to the first investigational drug administration; f) History of clinically significant bleeding symptoms within 1 month prior to the first study drug administration; g) Imaging at screening shows tumor encasement of major vessels or presence of significant necrosis or cavitation, and the investigator judges that enrollment would increase the risk of bleeding.
  17. The subject has a history of hematopoietic stem cell transplantation or solid organ transplantation.
  18. The subject has a history of substance abuse or a mental disorder that may affect compliance with the study.
  19. Pregnant or breastfeeding women, where pregnancy is defined as the period from conception until the termination of pregnancy, and confirmed by a laboratory human chorionic gonadotropin (hCG) test within 7 days prior to the start of the study.
  20. Other conditions deemed unsuitable for participation in this study by the investigator.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
186 participants (estimated)

Study arms

  • Experimental
    DR30206+Oxaliplatin+Capecitabine

    DR30206 20mpk Q3W or DR30206 30mpk Q3W; Oxaliplatin 130 mg/m2, d1, Q3W; Capecitabine 1000 mg/m2, bid, d1-14, Q3W;

    Drug: DR30206 · Drug: Oxaliplatin · Drug: Capecitabine

  • Experimental
    DR30206+Oxaliplatin+Calcium Folinate+5-FU

    DR30206 15mpk Q2W or DR30206 20mpk Q2W; Oxaliplatin 85 mg/m2, d1, Q2W; Calcium Folinate 400mg/m2, d1, Q2W; 5-FU 400mg/m2, d1 and 5-FU 1200mg/m2, d2-3, Q2W.

    Drug: DR30206 · Drug: Oxaliplatin · Drug: Calcium Folinate · Drug: 5-FU

  • Experimental
    DR30206+Irinotecan+Calcium Folinate+5-FU

    DR30206 15mpk Q2W or DR30206 20mpk Q2W; Irinotecan 180 mg/m2, d1, Q2W; Calcium Folinate 400mg/m2, d1, Q2W; 5-FU 400mg/m2, d1 and 5-FU 1200mg/m2, d2-3, Q2W.

    Drug: DR30206 · Drug: Calcium Folinate · Drug: 5-FU · Drug: Irinotecan (CPT-11)

Interventions

  • DrugDR30206

    Subjects receive DR30206 intravenously

  • Subjects receive Oxaliplatin intravenously

  • Subjects take Capecitabine orally

  • Subjects receive Calcium Folinate intravenously

  • Drug5-FU

    Subjects receive 5-FU by Intravenous Bolus

  • Subjects receive Irinotecan intravenously

06

What researchers measure

Primary outcomes

  1. Phase Ib: Incidence of dose limiting toxicities (DLTs)

    Dose-limiting describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.

    Time frame: 21 days or 28 days following first dose according to the arms.

  2. Phase Ib: Incidence and severity of treatment-emergent adverse events (TEAEs)

    The incidence and severity of AEs graded according to NCI-CTCAE v5.0.

    Time frame: From the first dose up to 90 days after the last dose or initiation of new anti-tumor treatment

  3. Phase Ib: Maximum tolerated dose(MTD)

    As measured by number of participants experiencing dose related toxicity (DLT) in each escalating cohort.

    Time frame: 21 days or 28 days following first dose according to the arms.

  4. Phase Ib: Recommended phase 2 dose (RP2D)

    A recommended phase 2 dose will be determined based on safety data.

    Time frame: 21 days or 28 days following first dose according to the arms.

  5. Phase IIa: Objective response rate (ORR) (RECIST v1.1) of DR30206 in combination with standard therapy for the treatment of other gastrointestinal tumors

    Objective response rate (ORR) is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1

    Time frame: the period from the date of initial medication to the objective recording of disease progression according to RECIST 1.1 standards or to the start of new anti-tumor treatment (whichever occurs first)

  6. Phase IIa: Objective response rate (ORR) (RECIST v1.1) of DR30206 in combination with standard therapy for the treatment of advanced or metastatic colorectal cancer.

    Objective response rate (ORR) is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1

    Time frame: the period from the date of initial medication to the objective recording of disease progression according to RECIST 1.1 standards or to the start of new anti-tumor treatment (whichever occurs first), assessed up to 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Apr 2027, 25 months after the start.

Of 36 phase 1/2 interventional studies under Gastrointestinal Neoplasms, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2025
First posted
Jul 9, 2025
StartActual
Mar 25, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07056777
Responsible party
Sponsor
First posted
Jul 9, 2025
Start date
Mar 25, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jun 30, 2026

Study contacts

Yulong Gan Clinical Operations Director
Contact
yg@doerbio.com
+8615194402868
Yongliang Fang Chief Operating Officer
Contact
yf@doerbio.com
+86057128256206
Yanshan Huang CEO
study chair · Zhejiang Doer Biologics Co., Ltd.
Ruihua Xu
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion